Neonc Technologies Holdings Inc.
Publicly observedCalabasas, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Calabasas | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Neonc Technologies Holdings Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | XLZVF5LX5JM8 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant7 Aug 2025Publicly observed
NIH SBIR/STTR award: Development of NEO212, A Novel Oral Drug for the Treatment of Acute Myeloid Leukemia
USD 399,998.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Apr 2020Publicly observed
NIH SBIR/STTR award: Developing a Clinically Relevant Radiosensitizer for Temozolomide-resistant Gliomas
USD 1,033,906.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Apr 2020Publicly observed
NIH SBIR/STTR award: Developing a Clinically Relevant Radiosensitizer for Temozolomide-resistant Gliomas
USD 1,007,612.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.